Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
NEW YORK Drug maker Pfizer said Sunday it would immediately stop advertising its best-selling arthritis pain reliever Celebrex to consumers after a study showed high doses of it were associated with an increased heart attack risk.
New York-based Pfizer spent more than $70 million advertising Celebrex to U.S. consumers in the first nine months of this year.
Publicis Groupe’s Kaplan Thaler Group here handles ads for the brand. The agency’s first work for Celebrex broke in October.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in